Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4671)
All Articles published online
|
Feb 14, 2012 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Frenette C, Gish R. Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications. World J Gastroenterol 2012; 18(6): 498-506 [PMID: 22363115 DOI: 10.3748/wjg.v18.i6.498] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v18/i6/498.htm |
| Number | Citing Articles |
| 1 |
Seulki Lee, Minjong Lee, Jong Bin Kim, Ara Jo, Eun Ju Cho, Su Jong Yu, Jeong-Hoon Lee, Jung-Hwan Yoon, Yoon Jun Kim. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. Biochemical and Biophysical Research Communications 2016; 473(4): 1247 doi: 10.1016/j.bbrc.2016.04.049
|
| 2 |
ZS Guo, CL Jin, ZJ Yao, YM Wang, BT Xu. Analysis of the mitochondrial 4977 bp deletion in patients with hepatocellular carcinoma. Balkan Journal of Medical Genetics 2017; 20(1): 81 doi: 10.1515/bjmg-2017-0006
|
| 3 |
JEHOON YANG, KYOUNG DOO SONG, JAE-HUN KIM, GEUN-HO IM, SEULGI YOON, MISUN NAMGUNG, JUNG-HYUN HWANG, JUNG HEE LEE, DONGIL CHOI. Characterization of brivanib therapy response in hepatocellular carcinoma xenografts using 1H HR-MAS spectroscopy and histopathology. Molecular Medicine Reports 2013; 8(5): 1425 doi: 10.3892/mmr.2013.1690
|
| 4 |
Amanda Psyrri, Nikolaos Arkadopoulos, Maria Vassilakopoulou, Vassilios Smyrniotis, George Dimitriadis. Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2012; 12(10): 1347 doi: 10.1586/era.12.113
|
| 5 |
Roberta Montalbano, Petra Waldegger, Karl Quint, Samir Jabari, Daniel Neureiter, Romana Illig, Matthias Ocker, Pietro Di Fazio. Endoplasmic Reticulum Stress Plays a Pivotal Role in Cell Death Mediated by the Pan-Deacetylase Inhibitor Panobinostat in Human Hepatocellular Cancer Cells. Translational Oncology 2013; 6(2): 143 doi: 10.1593/tlo.12271
|
| 6 |
Samantha A. Armstrong, Aiwu Ruth He. Immuno-oncology for Hepatocellular Carcinoma. Clinics in Liver Disease 2020; 24(4): 739 doi: 10.1016/j.cld.2020.07.007
|
| 7 |
Jean-Marc Idée, Boris Guiu. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. Critical Reviews in Oncology/Hematology 2013; 88(3): 530 doi: 10.1016/j.critrevonc.2013.07.003
|
| 8 |
Ambreen Ayub, Usman Ali Ashfaq, Asma Haque. HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level. BioMed Research International 2013; 2013: 1 doi: 10.1155/2013/810461
|
| 9 |
Ruifang Wang, Xiaobo Hu, Xiaorui Liu, Lu Bai, Junsheng Gu, Qinggang Li, Edwin Wang. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis. PLOS ONE 2021; 16(4): e0249881 doi: 10.1371/journal.pone.0249881
|
| 10 |
Raewyn M. Poole, Asha Vaidya. Ramucirumab: First Global Approval. Drugs 2014; 74(9): 1047 doi: 10.1007/s40265-014-0244-2
|
| 11 |
Ping Fang, Jin-hua Hu, Zhi-gang Cheng, Zhe-feng Liu, Jin-liang Wang, Shun-chang Jiao, Xiaolin Zi. Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials. PLoS ONE 2012; 7(12): e49717 doi: 10.1371/journal.pone.0049717
|
| 12 |
Nitin Ohri, Andreas Kaubisch, Madhur Garg, Chandan Guha. Targeted Therapy for Hepatocellular Carcinoma. Seminars in Radiation Oncology 2016; 26(4): 338 doi: 10.1016/j.semradonc.2016.06.004
|
| 13 |
Gaurab Roy, Su Guan, Hexiang Liu, Lei Zhang. Rotundic Acid Induces DNA Damage and Cell Death in Hepatocellular Carcinoma Through AKT/mTOR and MAPK Pathways. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00545
|
| 14 |
Brian I. Carr. Some New Approaches to the Management of Hepatocellular Carcinoma. Seminars in Oncology 2012; 39(4): 369 doi: 10.1053/j.seminoncol.2012.05.007
|
| 15 |
Jianzhen Lin, Liangcai Wu, Xue Bai, Yuan Xie, Anqiang Wang, Haohai Zhang, Xiaobo Yang, Xueshuai Wan, Xin Lu, Xinting Sang, Haitao Zhao. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016; 7(43): 71036 doi: 10.18632/oncotarget.11954
|
| 16 |
Chi-Yuan Chen, Chin-Chuan Chen, Wen-Yu Chuang, Yann-Lii Leu, Shir-Hwa Ueng, Chuen Hsueh, Chau-Ting Yeh, Tong-Hong Wang. Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00216
|
| 17 |
Takuji Okusaka, Taiga Otsuka, Hideki Ueno, Shuichi Mitsunaga, Rie Sugimoto, Kei Muro, Isao Saito, Yusuke Tadayasu, Kohei Inoue, Arsene‐Bienvenu Loembé, Masafumi Ikeda. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Science 2016; 107(12): 1791 doi: 10.1111/cas.13077
|
| 18 |
Nitin Ohri, Laura A. Dawson, Sunil Krishnan, Jinsil Seong, Jason C. Cheng, Shiv K. Sarin, Milan Kinkhabwala, Mansoor M. Ahmed, Bhadrasain Vikram, C. Norman Coleman, Chandan Guha. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. Journal of the National Cancer Institute 2016; 108(9): djw133 doi: 10.1093/jnci/djw133
|
| 19 |
Zhengyu Wei, Cataldo Doria, Yuan Liu. Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma. Clinical Medicine Insights: Oncology 2013; 7: CMO.S7633 doi: 10.4137/CMO.S7633
|
| 20 |
Fang Su, Jun Zhao, Shukui Qin, Rui Wang, Yumei Li, Qiang Wang, Yi Tan, Hao Jin, Fangquan Zhu, Yurong Ou, Zenong Cheng, Wen Su, Fuyou Zhao, Yan Yang, Zhengguang Zhou, Jiyue Zheng, Yawei Li, Zhongwen Li, Qiong Wu. Over-expression of Thrombospondin 4 correlates with loss of miR-142 and contributes to migration and vascular invasion of advanced hepatocellular carcinoma. Oncotarget 2017; 8(14): 23277 doi: 10.18632/oncotarget.15054
|
| 21 |
Yusuke Shimodaira, Elena Elimova, Roopma Wadhwa, Hironori Shiozaki, Nikolaos Charalampakis, Venkatram Planjery, Mariela A Blum, Jeannelyn S Esteralla, Jane E Rogers, Shumei Song, Jaffer A Ajani. Ramucirumab for the treatment of gastroesophageal cancers. Expert Opinion on Orphan Drugs 2015; 3(6): 737 doi: 10.1517/21678707.2015.1040390
|
| 22 |
KUO-SHYANG JENG, CHI-JUEI JENG, WEN-JUEI JENG, I-SHYAN SHEEN, SHIH-YUN LI, ZIH-HANG HUNG, HSIN-I HSIAU, MING-CHE YU, CHIUNG-FANG CHANG. Liver epithelial cells inhibit proliferation and invasiveness of hepatoma cells. Oncology Reports 2016; 35(3): 1622 doi: 10.3892/or.2015.4478
|
| 23 |
Stefano Colagrande, Francesco Regini, Gian Giacomo Taliani, Cosimo Nardi, Andrea Lorenzo Inghilesi. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World Journal of Hepatology 2015; 7(8): 1041-1053 doi: 10.4254/wjh.v7.i8.1041
|
| 24 |
Mohammed K. AbdElhameid, Madlen B. Labib, Ahmed T. Negmeldin, Muhammad Al-Shorbagy, Manal R. Mohammed. Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 2018; 33(1): 1472 doi: 10.1080/14756366.2018.1503654
|
| 25 |
Maria Luisa Bondì, Chiara Botto, Erika Amore, Maria Rita Emma, Giuseppa Augello, Emanuela Fabiola Craparo, Melchiorre Cervello. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells. International Journal of Pharmaceutics 2015; 493(1-2): 75 doi: 10.1016/j.ijpharm.2015.07.055
|
| 26 |
Michael S Nastasie, Helmut Thissen, David A Jans, Kylie M Wagstaff. Enhanced tumour cell nuclear targeting in a tumour progression model. BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1045-z
|
| 27 |
Max M. Wattenberg, Nevena Damjanov, David E. Kaplan. Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience. Cancer Medicine 2019; 8(4): 1442 doi: 10.1002/cam4.2015
|
| 28 |
Christophe Duvoux, Christian Toso. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?. Transplantation Reviews 2015; 29(3): 168 doi: 10.1016/j.trre.2015.02.003
|
| 29 |
Sally Temraz, Ali T. Taher. Liver Cancer in the Middle East. 2021; : 375 doi: 10.1007/978-3-030-78737-0_24
|
| 30 |
Letao Lin, Pan Hu, Ma Luo, Xi Chen, Meigui Xiao, Zhihui Zhong, Sheng Peng, Guanyu Chen, Guang Yang, Fujun Zhang, Yanling Zhang. CircNOP14 increases the radiosensitivity of hepatocellular carcinoma via inhibition of Ku70-dependent DNA damage repair. International Journal of Biological Macromolecules 2024; 264: 130541 doi: 10.1016/j.ijbiomac.2024.130541
|
| 31 |
Giovanni Galati, Antonio Fabio Massimo Vainieri, Claudia Angela Maria Fulgenzi, Stefano Di Donato, Marianna Silletta, Paolo Gallo, Angelo Onorato, Umberto Vespasiani-Gentilucci, Antonio Picardi. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Current Drug Metabolism 2020; 21(11): 866 doi: 10.2174/1389200221999200918141239
|
| 32 |
Malek Kreidieh, Youssef H. Zeidan, Ali Shamseddine. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. Journal of Oncology 2019; 2019: 1 doi: 10.1155/2019/4304817
|
| 33 |
Anna C. Krelle, Arinze S. Okoli, George L. Mendz. Huh-7 Human Liver Cancer Cells: A Model System to Understand Hepatocellular Carcinoma and Therapy. Journal of Cancer Therapy 2013; 4(02): 606 doi: 10.4236/jct.2013.42078
|
| 34 |
Andrzej Krol, Barjor Gimi, Qian Liang, Jinzuo Ye, Yang Du, Chongwei Chi, Jie Tian.
Evaluation of the anti-neoplastic effect of sorafenib on liver cancer through bioluminescence tomography
. Medical Imaging 2017: Biomedical Applications in Molecular, Structural, and Functional Imaging 2017; 10137: 1013702 doi: 10.1117/12.2254323
|
| 35 |
Tamer Elbaz, Mohamed El Kassas, Gamal Esmat. Management of Hepatocellular Carcinoma: Updated Review. Journal of Cancer Therapy 2013; 4(02): 536 doi: 10.4236/jct.2013.42067
|
| 36 |
Giuseppe Aprile, Marta Bonotto, Elena Ongaro, Carmelo Pozzo, Francesco Giuliani. Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use. Drugs 2013; 73(18): 2003 doi: 10.1007/s40265-013-0154-8
|
| 37 |
Marco Baron Toaldo, Veronica Salvatore, Sara Marinelli, Chiara Palamà, Maddalena Milazzo, Luca Croci, Laura Venerandi, Mario Cipone, Luigi Bolondi, Fabio Piscaglia. Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. Molecular Imaging and Biology 2015; 17(1): 29 doi: 10.1007/s11307-014-0764-x
|
| 38 |
Qi-Zhe Gong, Di Xiao, Gui-Yi Gong, Jian Xu, Xiao-Dong Wen, Feng Feng, Wei Qu. EH-42: A Novel Small Molecule Induces Apoptosis and Inhibits Migration and Invasion of Human Hepatoma Cells through Suppressing STAT3 Signaling Pathway. Current Cancer Drug Targets 2019; 19(7): 583 doi: 10.2174/1568009619666181226094814
|